Neoadjuvant/Adjuvant Doublet Significantly Improved Survival in Patients With Muscle-Invasive Bladder Cancer - Takeaway - MDSpire
From the Journals
Conference News

Neoadjuvant/Adjuvant Doublet Significantly Improved Survival in Patients With Muscle-Invasive Bladder Cancer

The combination of the NECTIN4-directed antibody drug conjugate enfortumab vedotin-ejfv and the immunotherapy drug pembrolizumab is the established first-line standard-of-care treatment for patients w...

Share

  • 1

    Enfortumab vedotin plus pembrolizumab improves survival rates.

  • 2

    Phase III KEYNOTE-B15 study involved 808 patients.

  • 3

    Significant improvement in event-free survival noted.

  • 4

    Pathologic complete response rate higher in treatment group.

  • 5

    Grade ≥ 3 adverse events reported in 75.7% of patients.

Original Source(s)

Neoadjuvant/Adjuvant Doublet Significantly Improved Survival in Patients With Muscle-Invasive Bladder Cancer

  • by Jo Cavallo

  • April 17, 2026

Related Content

Trends and Challenges in Nitrosamine Testing Part Four The Regulatory Landscape

Following part two, which explored the analytical challenges involved in nitrosamine testing, our experts return to offer their top tips for building a method from scratch

  • April 17, 2026

  • 6 min
Is Standard of Care Optimal for the Individual Patient?

I am writing this from the hospital waiting room. My father is undergoing an 11-hour surgery to remove his parotid gland and a squamous cell carcinoma that has metastasized from his cheek and invaded ...

Dana-Farber Research News 04.15.2026

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from March 16 - 31.

  • by

  • April 15, 2026

  • 22 min